TAKITA Morichika
Department School of Medicine, School of Medicine Position Assistant Professor |
|
Article types | Original article |
Language | English |
Peer review | Peer reviewed |
Title | Drug Targeting Based on a New Concept-Targeting Against TLR4 as an Example. |
Journal | Formal name:Endocrine, metabolic & immune disorders drug targets Abbreviation:Endocr Metab Immune Disord Drug Targets ISSN code:18715303/22123873 |
Volume, Issue, Page | 15(2),pp.83-87 |
Author and coauthor | Maru Yoshiro, Tomita Takeshi*, Deguchi Atsuko, Ieguchi Katsuaki, Takita Morichika, Tsukahara Fujiko, Takemura Kazuhiro, Kitao Akio, Gusovsky Fabian |
Publication date | 2015 |
Summary | TLRs are very important players to regulate innate immune responses. TLR4 controls the host defense by sensing an exotic pathogen, such as lipopolysaccharides. At the same time, some endogenous proteins, including HMGB1 and S100A8, could also function to be a ligand to elicit inflammatory reactions. These facts make TLR4 signaling system very complicated. For instance, the application of TLR4 ligands in cancer therapies is desirable for enhancement of anti-tumor immunity in terms of its reparative nature, but undesirable for enhancement of metastatic growth of cancer cells. In this manuscript, in order to make a novel molecular design to disrupt an interaction between TLR4/MD-2 and endogenous ligands, we provide a potential binding style of the TLR4/MD-2 complex with HMGB1 by using their 3D structural data and docking simulations, and also discuss S100A8 binding to TLR4/MD-2. |
DOI | 10.2174/187153031502150522123746 |
PMID | 26004773 |